首页> 外文期刊>Journal of hypertension >Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats.
【24h】

Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats.

机译:钠盐限制的单肾一夹式高血压大鼠中慢性奥马驰醇的全身和肾脏作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: The systemic and renal effect of omapatrilat was evaluated and compared with that of enalapril (30 and 10 mg/kg per day) in sodium-depleted, one-kidney, one-clip hypertensive rats. Participation of kinins was assessed by concomitant infusion of Hoe140 (300 microg/kg per day). DESIGN: Four weeks after clipping and uninephrectomy, dietary sodium was withdrawn for 2 weeks and rats were treated during the last 6 days of the study. METHODS: Tail-cuff pressure and sodium excretion were determined in conscious rats. Glomerular filtration rate (GFR) and renal plasma flow (RPF) were determined in anesthetized rats using clearance methods. The heart weight index was calculated. RESULTS: Omapatrilat was as effective as enalapril in reducing arterial pressure, and Hoe140 had no influence. Natriuresis increased to a similar extent with omapatrilat and enalapril. Hoe140 prevented the sodium loss only in enalapril-treated rats. Compared with untreated rats, GFR was reduced to a lesser extent by omapatrilatthan enalapril (694 +/- 93 and 364 +/- 40 versus 848 +/- 43 microl/min per g kidney weight). Hoe140 had no influence on GFR in omapatrilat-treated animals but attenuated the reduction of GFR in enalapril-treated rats (662 +/- 22 and 543 +/- 62 microl/min per g kidney weight). Since RPF was not significantly affected, reduction of the filtration fraction was more marked in enalapril- than omapatrilat-treated rats (60 and 28%, respectively). Heart weight index was lower in omapatrilat-treated rats than in untreated or enalapril-treated rats. Hoe140 failed to significantly obliterate the antihypertrophic effect of omapatrilat. CONCLUSION: These results suggest that accumulation of natriuretic peptides due to neutral endopeptidase inhibition participated in the antihypertrophic effect of omapatrilat and tended to counteract the deleterious effect of ACE inhibition on renal function.
机译:目的:评估奥马帕特立对钠缺乏,单肾,单夹子高血压大鼠的全身和肾脏作用,并与依那普利(每天30和10 mg / kg)进行比较。通过同时输注Hoe140(每天300微克/千克)来评估激肽的参与。设计:修剪和单肾切除术后四个星期,饮食中的钠被撤出2周,在研究的最后6天对大鼠进行治疗。方法:测定清醒大鼠的尾袖压和钠排泄量。使用清除方法测定麻醉大鼠的肾小球滤过率(GFR)和肾血浆流量(RPF)。计算心脏重量指数。结果:Omapatrilat在降低动脉压方面与依那普利同样有效,而Hoe140则没有影响。与奥马替利和依那普利相比,利钠尿症增加的程度相似。 Hoe140仅在依那普利治疗的大鼠中预防钠损失。与未治疗的大鼠相比,奥马帕拉非尼比依那普利降低的GFR程度较小(每克肾脏重量694 +/- 93和364 +/- 40对848 +/- 43微升/分钟)。 Hoe140对经奥马帕替尼治疗的动物的GFR没有影响,但减弱了依那普利治疗的大鼠的GFR降低(每克肾脏重量662 +/- 22和543 +/- 62 microl / min)。由于RPF并未受到显着影响,因此依那普利治疗组大鼠的滤过率降低幅度明显高于奥马帕来立特治疗组(分别为60%和28%)。用奥马帕特立治疗的大鼠的心脏重量指数低于未治疗或依那普利治疗的大鼠。 Hoe140无法显着消除omapatrilat的抗肥大作用。结论:这些结果表明,中性内肽酶抑制引起的利钠肽的积累参与了奥马替拉酸的抗肥大作用,并倾向于抵消ACE抑制对肾功能的有害作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号